Navigation Links
Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
Date:4/14/2008

Nonclinical Studies Demonstrate that SNS-595 Acts through a Dual Mechanism

and May Evade Common Drug Resistance Mechanisms

Research Supports Current Clinical Development of SNS-595 in AML and

Ovarian Cancer and Potential in Additional Indications

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today presented nonclinical data on SNS-595's unique mechanism of action and its anticancer activity at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 in combination with cytarabine in relapsed/refractory acute myeloid leukemia (AML) are both ongoing.

"Data presented today provide important new insights into SNS-595's mechanism as a site-selective DNA intercalator and topoisomerase poison with selectivity for proliferating cells. Through its unique chemical structure and molecular mechanism, SNS-595 avoids common drug resistance pathways and may have advantages over other topoisomerase poisons," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer. "Taken together, these data support our ongoing clinical trials of SNS-595 in platinum-resistant ovarian cancer and acute myeloid leukemia, and provide compelling evidence for future studies of SNS-595 in indications such as breast cancer where topoisomerase II poisons are active."

Sunesis researchers conducted in vitro and cell-based studies elucidating SNS-595's mechanism of action. SNS-595 selectively intercalates DNA and poisons topoisomerase II, resulting in replication-dependent DNA damage, irreversi
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
2. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
6. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
7. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2008)... Dr. Alan Greene from the kids, health we...ating only organic food. It,s the same benchmark t...ic. , Danville, CA (PRWEB...ertified organic by the Department of Agriculture ...Alan Greene, why not people?, , , , ,In an articl...
(Date:12/4/2008)... Cell Therapeutics, Inc. ...oday announced that that its Board,of Directors h...fer to,purchase a portion or all of five series o... , -- 4% Convertible Senior Subordinated Note...due 2011, -- 6.75% Convertible Senior Notes du...
(Date:12/4/2008)...n of lung disease in cystic fibrosis (CF), combine... key to controlling the progression of the disease...that contrary to previous scientific opinion, prog...rly as infancy even though lung function shortly a...o stop some of the lung function reduction we,re i...
(Date:12/4/2008)...ec. 4 In the 1983 movie... the world that a Red Ryder BB gun is the perfect ...the response he got from his parents, teacher and ...nd memorable quotes from this Christmas classic be...ldhood. And unfortunately, it comes true for too m...
Breaking Medicine News(10 mins):Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 2Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 3Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 2Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 3Health News:Intervention in infants with cystic fibrosis key to slowing progression 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 3Health News:Texas Parents Can Prevent Holiday Tragedies with Safe Toys and Celebrations 2
... University of Liverpool had proposed that patient...t from medication.// They say that it is advisable...ptic patients. Researchers of the study feel that ...ficantly benefit the patients in having a better q...
...ccess of the World Health Day 2000 with the theme ...orld Blood Donors Day.// The date coincides with t...the ABO blood group system. The International Bl...y by the International Federation of Blood Donor O...
... analysis has been developed as a tool to diagnose...and Harvard. Researchers have also been able to de...icroRNA profile through an easy and not expensive ... small RNA molecules that control the level of pro...
...n reduce the rate of negative appendectomy by a si... imaging is also known as Computerized Axial Tomog...sectional images that may be used as a diagnostic ...iseases and health conditions. Negative appendecto...
Other Medicine News:
(Date:12/2/2008)...ire-USNewswire/ -- Researchers using functional,M...e area of the brain,responsible for suppressing m...,stress-related psychiatric disorders. Results of ...eeting of the Radiological Society of North Americ...ssion and other stress-related disorders,traumat...
(Date:12/2/2008)...Newswire/ -- Horizon Therapeutics, Inc., a,privat...d that two pivotal,Phase 3 trials evaluating its ...met all primary endpoints. HZT-501, a novel, propr...ibuprofen and famotidine, demonstrated a,statisti...n-steroidal,anti-inflammatory drug (NSAID)-induce...
(Date:12/1/2008)...swire/ -- TargeGen has announced that an oral,pre...ter, US-based clinical,trial of TG101348 in myelo...at,the 2008 American Society of Hematology (ASH) ...e as follows:, Title: A Phase I... JAK2-Selective Inhibitor, in Pat...
(Date:12/1/2008)...l the best policy , , ROCHESTER, Minn., De...ayo Clinic finds the use of the drug therapy etane... an acute inflammation of the liver caused by exce...tudy are published in the December issue of Gastr..., , VIDEO ALERT: Additional audio and video ...
Breaking Medicine Technology:Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3 AxoGen Awarded Accreditation from American Association of Tissue Banks 3A Decision Affirms AxoGen 26apos 3Bs Commitment to Safety and Ethicality in 26911 1 AxoGen Awarded Accreditation from American Association of Tissue Banks 3A Decision Affirms AxoGen 26apos 3Bs Commitment to Safety and Ethicality in 26911 2 AxoGen Awarded Accreditation from American Association of Tissue Banks 3A Decision Affirms AxoGen 26apos 3Bs Commitment to Safety and Ethicality in 26911 3Evidence Based Investing 3A M D Turned Financial Advisor Diagnoses What Ails Most Investors 26907 1Evidence Based Investing 3A M D Turned Financial Advisor Diagnoses What Ails Most Investors 26907 2Evidence Based Investing 3A M D Turned Financial Advisor Diagnoses What Ails Most Investors 26907 3Evidence Based Investing 3A M D Turned Financial Advisor Diagnoses What Ails Most Investors 26907 4Evidence Based Investing 3A M D Turned Financial Advisor Diagnoses What Ails Most Investors 26907 5Safety Threat to Rochester Still Remains Despite Approval Of Canadian Pacifics Railroad Acquisition Of DM 26E 26903 1Safety Threat to Rochester Still Remains Despite Approval Of Canadian Pacifics Railroad Acquisition Of DM 26E 26903 2Safety Threat to Rochester Still Remains Despite Approval Of Canadian Pacifics Railroad Acquisition Of DM 26E 26903 3Walking forum report shows need to expand physical activity in schools 26900 1Walking forum report shows need to expand physical activity in schools 26900 2Walking forum report shows need to expand physical activity in schools 26900 3Walking forum report shows need to expand physical activity in schools 26900 4Walking forum report shows need to expand physical activity in schools 26900 5
...ificantly Reduced Signs of Disease Activity as Mea...ay 1, 2007 -- Genentech, Inc.,(NYSE: DNA) and Bi...tive data from a Phase II clinical study of Rituxa...tting multiple sclerosis,(RRMS) were presented tod...ting held in Boston. Rituxan is a therapeutic anti...
...INESS WIRE)--May 1, 2007 - Significantly more pati...in by 50 percent or,more compared with placebo, ac...erican Academy of Neurology annual meeting.,Clinic...severe pain,reporting a reduction to mild to moder...chronic, widespread pain,conditions and is thought...
Other Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6Lyrica Significantly Reduced Pain and Helped Patients Manage the,Symptoms of Fibromyalgia, Data Show 2Lyrica Significantly Reduced Pain and Helped Patients Manage the,Symptoms of Fibromyalgia, Data Show 3
... at Once , To increase efficiency and throughput ... adapt to the narrow well spacing. Thats exactly w... Available with Impact or Impact2 software (see Im...signed to allow you to transfer an entire column o...
Designed to create a near bloodless field and provide myocardial protection during target vessel anastomosis. Its unique internal coil and tapered tip have been designed to allow easy, atraumatic ins
...y is used for cardiac and great vessel reconstruct...araldehyde-treated bovine pericardium and offers s...suturability and handling over synthetic patches. ... ability to prevent calcification and the complica...
Supreme and Response catheters comprise the world's broadest line of fixed-curve catheters available for electrophysiology procedures. Their advanced catheter design and materials technology provide
Medicine Products: